September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Monitoring treatment of retinal angiomatous proliferation by phase resolved Doppler OCT
Author Affiliations & Notes
  • Mirjam EJ Van Velthoven
    Ophthalmology, Rotterdam Eye Hospital, Rotterdam, Netherlands
  • Jan H. de Jong
    Ophthalmology, Rotterdam Eye Hospital, Rotterdam, Netherlands
  • Boy Braaf
    VU University, Amsterdam, Netherlands
  • Maximilian Gräfe
    VU University, Amsterdam, Netherlands
  • Sankha Amarakoon
    Ophthalmology, Rotterdam Eye Hospital, Rotterdam, Netherlands
  • Koenraad Arndt Vermeer
    Ophthalmology, Rotterdam Eye Hospital, Rotterdam, Netherlands
  • suzanne yzer
    Ophthalmology, Rotterdam Eye Hospital, Rotterdam, Netherlands
  • Tom Missotten
    Ophthalmology, Rotterdam Eye Hospital, Rotterdam, Netherlands
  • Johannes F De Boer
    VU University, Amsterdam, Netherlands
  • Footnotes
    Commercial Relationships   Mirjam Van Velthoven, Allergan Europe (R), Novartis Netherlands (R); Jan de Jong, None; Boy Braaf, None; Maximilian Gräfe, None; Sankha Amarakoon, None; Koenraad Vermeer, None; suzanne yzer, None; Tom Missotten, None; Johannes De Boer, Heidelberg Engineering (F), Massachusetts General Hospital (P)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 1615. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Mirjam EJ Van Velthoven, Jan H. de Jong, Boy Braaf, Maximilian Gräfe, Sankha Amarakoon, Koenraad Arndt Vermeer, suzanne yzer, Tom Missotten, Johannes F De Boer; Monitoring treatment of retinal angiomatous proliferation by phase resolved Doppler OCT. Invest. Ophthalmol. Vis. Sci. 2016;57(12):1615.

      Download citation file:


      © 2017 Association for Research in Vision and Ophthalmology.

      ×
  • Supplements
Abstract

Purpose : In contrast to most conventional imaging techniques, Doppler OCT is able to provide depth-resolved information about intra- and transretinal blood flow non-invasively. We performed an exploratory prospective, observational cohort study to evaluate Doppler OCT for monitoring the effect of treatment in patients with retinal angiomatous proliferation (type 3 CNV).

Methods : Twelve treatment-naïve patients were included, with a median age of 79 years (range 65-90). They were diagnosed with type 3 CNV based on fundus examination, fluorescein angiography and indocyanine-green angiography. Patients were additionally imaged with an experimental 1040 nm swept-source phase resolved Doppler OCT instrument before and after treatment. Patients were treated with either intravitreal bevacizumab or triamcinolone injection(s) with or without photodynamic therapy (PDT). Abnormal blood flow after treatment was defined as unchanged, decreased or absent.

Results : Good quality Doppler OCT images before and after treatment could be obtained in 9 patients. After the first treatment series the type 3 CNV lesion was absent in 7 patients, in 1 patient the Doppler OCT depicted decreased flow in the lesion and 1 patient showed unchanged abnormal blood flow. Only in 1 out of 4 patients complete resolution was seen after a single bevacizumab injection. Combined therapy of bevacizumab with PDT showed complete resolution in 5 out of 5 patients (see figure).

Conclusions : Doppler OCT is able to detect changes in abnormal blood flow after treatment of type 3 CNV. This type of imaging may become an important non-invasive monitoring tool for optimizing treatment strategies in type 3 CNV patients and possibly in other types of macular degeneration.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

 

Doppler en face (left) and tomogram (right) of abnormal intraretinal blood flow continuous to the sub-retinal pigment epithelial (RPE) region at the top of a pigment epithelial detachment (PED). The tomogram position is indicated by a red dotted line in the en face image (left). The Doppler flow information is superimposed in red over the grayscale structural OCT tomogram (right). Top: baseline. Middle: persisting abnormal flow after a single bevacizumab injection. Bottom: Resolution of abnormal flow after additional PDT treatment. The consecutive en face Doppler images (left) show gradual disappearance of the abnormal vascular network.

Doppler en face (left) and tomogram (right) of abnormal intraretinal blood flow continuous to the sub-retinal pigment epithelial (RPE) region at the top of a pigment epithelial detachment (PED). The tomogram position is indicated by a red dotted line in the en face image (left). The Doppler flow information is superimposed in red over the grayscale structural OCT tomogram (right). Top: baseline. Middle: persisting abnormal flow after a single bevacizumab injection. Bottom: Resolution of abnormal flow after additional PDT treatment. The consecutive en face Doppler images (left) show gradual disappearance of the abnormal vascular network.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×